Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dofetilide is a class III antiarrhythmic agent used to treat irregular heartbeats, specifically atrial fibrillation and atrial flutter. It works by selectively blocking the rapid component of the delayed rectifier outward potassium current (IKr), which increases the refractory period of atrial tissue and helps restore and maintain normal sinus rhythm. Dofetilide does not affect conduction velocity or resting membrane potential. The drug is available as an oral capsule and requires close monitoring during initiation due to its potential to cause serious arrhythmias, including QT prolongation and torsade de pointes. Dofetilide is marketed under the brand name Tikosyn in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dofetilide.